Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group

Blood

Volumn 118, Issue 11, 2011, Pages 3080-3087

  Zhang, Jinghui ^a   Mullighan, Charles G ^a   Harvey, Richard C ^b   Wu, Gang ^a   Chen, Xiang ^a   Edmonson, Michael ^c   Buetow, Kenneth H ^c   Carroll, William L ^d   Chen, I Ming ^b   Devidas, Meenakshi ^e   Gerhard, Daniela S ^c   Loh, Mignon L ^f   Reaman, Gregory H ^g   Relling, Mary V ^a   Camitta, Bruce M ^h   Bowman, W Paul ⁱ   Smith, Malcolm A ^c   Willman, Cheryl L ^b   Downing, James R ^a   Hunger, Stephen P ^j,k  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^h CHILDREN S HOSPITAL OF WISCONSIN   (United States)

ⁱ Pediatric Cardiothoracic Surgery   (United States)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k CHILDREN S HOSPITAL COLORADO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; JANUS KINASE; MUCIN 4; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETV6;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADARB2 GENE; ARTICLE; ASMTL GENE; B LYMPHOCYTE DIFFERENTIATION; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CREBBP GENE; GENE; GENE DELETION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SOMATIC MUTATION; TBL1XR1 GENE;

EID: 80052922387     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-341412     Document Type: Article

References (49)

1. Moricke A, Zimmermann M, Reiter A, et al. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265-284.
2. Salzer WL, Devidas M, Carroll WL, et al. Longterm results of the Pediatric Oncology Group Studies for Childhood Acute Lymphoblastic Leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia. 2010;24(2):355-370.
3. Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008;22(12):2142-2150.
4. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009;27(31):5175-5181.
5. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470-480.
6. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009;106:9414-9418.
7. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/ Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-5321.
8. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric highrisk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010; 116(23):4874-4884.
9. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010;24(7):1258-1264.
10. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al.Asubtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genomewide classification study. Lancet Oncol. 2009;10(2):125-134.
11. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-2698.
12. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-1246.
13. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372(9648):1484-1492.
14. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-1671. (Pubitemid 28267911)
15. Shuster JJ, Camitta BM, Pullen J, et al. Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse. Cancer Res Ther Control. 1999;9:101-107. (Pubitemid 29408333)
16. Bowman WP, Larsen EL, Devidas M, et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906. Pediatr Blood Cancer. 2011;57(4):569-577.
17. Mullighan CG, Goorha S, Radtke I, et al. Genomewide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764. (Pubitemid 46582031)
18. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471(7337):235-239.
19. Ewing B, Hillier L, Wendl MC, Green P. Basecalling of automated sequencer traces using phred: I. Accuracy assessment. Genome Res. 1998;8(3):175-185. (Pubitemid 28177229)
20. Zhang J, Wheeler DA, Yakub I, et al. SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol. 2005;1(5): e53.
21. Zhang J, Finney RP, Rowe W, et al. Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). Genome Res. 2007;17(7):1111-1117. (Pubitemid 47026358)
22. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355-358. (Pubitemid 39037083)
23. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
25. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308-311. (Pubitemid 32054478)
26. Gump J, McGavran L, Wei Q, Hunger SP. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2001;23(7):416-419. (Pubitemid 33031768)
27. Case M, Matheson E, Minto L, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008;68(16):6803-6809.
28. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016):435-439.
29. Li J, Wang CY. TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nat Cell Biol. 2008;10(2):160-169. (Pubitemid 351194045)
30. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189-195.
31. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10(1):65-75.
32. Armstrong SA, Mabon ME, Silverman LB, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103(9):3544-3546. (Pubitemid 38525690)
33. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rear-rangements and pediatric ALL with hyperdiploidy. Blood. 2004;103(3):1085-1088. (Pubitemid 38129575)
34. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823-833. (Pubitemid 350006257)
35. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322 (5906):1377-1380. (Pubitemid 352775249)
36. Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemiainitiating cells. Nature. 2011;469(7330):362-367.
37. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330):356-361.
38. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011;208(4):653-661.
39. Yamamoto T, Isomura M, Xu Y, et al. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leuk Res. 2006;30(9):1085-1089. (Pubitemid 44037090)
40. Liang DC, Shih LY, Fu JF, et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer. 2006;106(4):950-956.
41. Wiemels JL, Zhang Y, Chang J, et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia. 2005;19(3):415-419. (Pubitemid 40403319)
42. Perentesis JP, Bhatia S, Boyle E, et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia. 2004;18(4):685-692. (Pubitemid 38500186)
43. Paulsson K, Horvat A, Strombeck B, et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2008;47(1):26-33. (Pubitemid 350191461)
44. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20(9):1496-1510. (Pubitemid 44264091)
45. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114(3):647-650.
46. Barjesteh van Waalwijk van Doorn-Khosrovani S, Spensberger D, de Knegt Y, Tang M, Lowenberg B, Delwel R. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene. 2005;24(25):4129-4137. (Pubitemid 40903096)
47. Parker H, An Q, Barber K, et al. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes Chromosomes Cancer. 2008;47(12):1118-1125.
48. Rowley JD, Reshmi S, Sobulo O, et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997;90(2):535-541. (Pubitemid 27299092)
49. Troke PJ, Kindle KB, Collins HM, Heery DM. MOZ fusion proteins in acute myeloid leukaemia. Biochem Soc Symp. 2006(73):23-39. (Pubitemid 44884510)